लोड हो रहा है...

Incidence and risk of hand–foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis

BACKGROUND: Cabozantinib is approved in the treatment of progessive, metastatic medullary thyroid cancer (MTC). It is a small molecule inhibitor, which targets multiple receptors including vascular endothelial growth factor receptor, tyrosine kinase with Ig and epidermal growth factor homology domai...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Clin Exp Dermatol
मुख्य लेखकों: Belum, V. R., Serna-Tamayo, C., Wu, S., Lacouture, M. E.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2015
विषय:
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC5066302/
https://ncbi.nlm.nih.gov/pubmed/26009777
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ced.12694
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!